Syneos Health (NASDAQ:SYNH) updated its FY18 earnings guidance on Wednesday. The company provided EPS guidance of $2.68-2.94 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.56. The company issued revenue guidance of $3.23-3.33 billion, compared to the consensus revenue estimate of $3.21 billion.Syneos Health also updated its Q1 guidance to $0.54-0.60 EPS.
Several research firms have issued reports on SYNH. BidaskClub upgraded Syneos Health from a sell rating to a hold rating in a research note on Thursday, December 7th. SunTrust Banks dropped their price objective on Syneos Health to $50.00 and set a buy rating on the stock in a research note on Friday, December 1st. Credit Suisse Group dropped their price objective on Syneos Health from $68.00 to $54.00 and set an outperform rating on the stock in a research note on Tuesday, November 14th. TheStreet downgraded Syneos Health from a b- rating to a c rating in a research report on Monday, December 18th. Finally, Robert W. Baird set a $50.00 target price on Syneos Health and gave the company a buy rating in a research report on Thursday, February 22nd. Three research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The stock presently has an average rating of Buy and a consensus target price of $48.89.
Syneos Health (NASDAQ SYNH) opened at $35.80 on Wednesday. Syneos Health has a 12-month low of $31.10 and a 12-month high of $61.10. The company has a debt-to-equity ratio of 0.99, a current ratio of 1.27 and a quick ratio of 1.27. The company has a market capitalization of $3,636.42, a P/E ratio of 15.99, a PEG ratio of 1.02 and a beta of 0.80.
About Syneos Health
Syneos Health, Inc, formerly INC Research Holdings, Inc, is a global contract research organization (CRO). The Company focuses on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services.
Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.